Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LEXINGTON, Mass., Aug. 31, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will present at Baird’s 2016 Global Healthcare Conference on September 7, 2016, at 7:55 a.m. Eastern Time in New York City.
The presentation will be held using a fireside-chat format in which Dr. Ali Fattaey, President and Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session.
A corresponding webcast of the presentation can be accessed by visiting:
http://wsw.com/webcast/baird46/cris
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. The company’s clinical drug candidates include CUDC-907, which is being investigated in a Phase 2 trial in patients with Diffuse Large B Cell Lymphoma, or DLBCL, and in a separate Phase 1 trial in patients with solid tumors. As part of a broad collaboration with Aurigene, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 and VISTA pathways, including the drug candidate PD-L1/VISTA antagonist CA-170, which is currently being investigated in a Phase 1 trial as a once daily oral capsule in patients with solid tumors or lymphoma. Curis also has an exclusive license to molecules designed to inhibit IRAK4, including CA-4948, currently in the pre-IND stage of development. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.
For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
